~~<i id='0BD71FF5CA'><strike id='0BD71FF5CA'><tt id='0BD71FF5CA'><pre id='0BD71FF5CA'></pre></tt></strike></i>~~

Home» explore» knowledge

knowledge

author：focus 2025-09-29 12:24:47 Page View：365

Novo Nordisk headquarters -- health coverage from STAT — LISELOTTE SABROE/Scanpix/AFP via Getty Images

LONDON — Novo Nordisk said Monday it would acquire the German firm Cardior Pharmaceuticals in a deal worth up to $1.1 billion, picking up additional drug candidates for its pipeline of cardiometabolic medicines.

Cardior focuses on targeting RNA to address the root causes of heart disease. Its lead candidate, known CDR132L, is in Phase 2 development as a treatment for health failure.

The companies did not disclose how much Novo was paying upfront for Cardior and how much would be based on future milestones being achieved. The deal is expected to close in the second quarter.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： HHS leader on health, climate change and biopharma emissions
Next article： State Dept. review finds Biden bears some blame for Afghanistan failures

knowledge

Wildfire smoke exposes gaps in outdoor worker protections

ApersonwaitingforthesubwaywearsafilteredmaskassmokyhazefromwildfiresinCanadablanketsaneighborhoodinN

Senate panel passes drug pricing bills, but drops one PBM reform

CommitteeRankingRepublicanBillCassidy(La.)andChairmanBernieSanders(I-Vt.)ChipSomodevilla/GettyImages

BioMarin wins approval for gene therapy to treat hemophilia A

AdobeTheFoodandDrugAdministrationonThursdayapprovedagenetherapytotreatpeoplewithhemophiliaA,aninheri

Science's Marcia McNutt, trailblazer for women, encounters sexism scandal

MarciaMcNutthasbeentappedtoleadtheNationalAcademyofSciences.DrewAngererforSTATThefirstwomantappedtol